Clarity SIGNED
Real-time renal diagnostic to prevent ICU-acquired Acute Kidney Injury (AKI).
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Clarity project word cloud
Explore the words cloud of the Clarity project. It provides you a very rough idea of what is the project "Clarity" about.
Project "Clarity" data sheet
The following table provides information about the project.
| Coordinator |
RENAL SENSE LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-11-01 to 2020-02-29 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | RENAL SENSE LTD | IL (JERUSALEM) | coordinator | 50˙000.00 |
Map
Project objective
Intensive Care Unit (ICU)-acquired Acute Kidney Injury (AKI) is a prevalent and serious problem, associated with significantly increased morbidity and mortality. According to the Global Burden of Disease (GBD), each year around 1.7 million people worldwide are estimated to die from AKI. AKI develops in over 57% of ICU patients, requiring an average of 3.5 additional hospital days and €13,000 of additional hospital costs per patient. The best treatment for AKI is prevention. Although there is no curative therapy for AKI, research over the past decade identified various means to prevent or limit AKI. Unfortunately, these are not widely known and are variably practiced worldwide resulting in lost opportunities to improve the care and outcomes of patients with AKI. RenalSense introduces Clarity RMS™, a critical care monitoring system that continuously measures urine flow, automatically transmitting to the medical staff real-time data and alerts of fluctuations, on a 24/7 basis. Using patented sensor technology, Clarity measures, analyses and interprets the continuously changing composition and flow volume of urine. This information, which reflects changes in renal function, provides an early sign of AKI risk and facilitates rapid intervention. In addition, it is invaluable for monitoring treatment efficacy and managing fluid balance. The system has been tested during clinical trials with Herzog hospital, Hadassah Medical Organisation and University of Pittsburgh. Analysis of 1,000 study hours showed that electronic measurements with Clarity were more consistent, reliable and accurate than nursing records. During the feasibility assessment, RenalSense will establish a go-to-market strategy, as well as a feasible product development plan and industrialization strategy. The plan for the large-scale clinical trials will be defined, and the participants secured.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLARITY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CLARITY" are provided by the European Opendata Portal: CORDIS opendata.